2006
DOI: 10.1530/eje.1.02218
|View full text |Cite
|
Sign up to set email alerts
|

Changes in bioactive IGF-I and IGF-binding protein-1 during an oral glucose tolerance test in patients with liver cirrhosis

Abstract: Objective :L iver cirrhosis is characterized by reduced circulating IGF-I and this has been linked to an adverse clinical outcome.Therefore, we investigated the dynamic changes in circulating total, free, and bioactiveI GF-I, IGF-binding protein (IGFBP)-1, IGFBP-2, and IGFBP-1-bound IGF-I (binarycomplex) during an oral glucose tolerance test (OGTT) in patients with liver cirrhosis. Methods:Seven Caucasian males with liver cirrhosis and seven healthymales matched for age (54.4G 3.2 vs 54.6G 4.4 years) and body … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

3
20
0

Year Published

2007
2007
2014
2014

Publication Types

Select...
7

Relationship

3
4

Authors

Journals

citations
Cited by 24 publications
(23 citation statements)
references
References 59 publications
(48 reference statements)
3
20
0
Order By: Relevance
“…Studies in the rat indicate that IGFBP-1 infusion inhibits muscle protein synthesis in fast-twitch muscle, although this was not shown in the heart (35). Potential determinants of elevated circulating IGFBP-1 in persons at risk for CHF include oxidative stress (15), cytokine activity (36, 37), ephinephrine or norepinephrine (38), and subclinical liver disease or hepatic insulin resistance (39).…”
Section: Discussionmentioning
confidence: 99%
“…Studies in the rat indicate that IGFBP-1 infusion inhibits muscle protein synthesis in fast-twitch muscle, although this was not shown in the heart (35). Potential determinants of elevated circulating IGFBP-1 in persons at risk for CHF include oxidative stress (15), cytokine activity (36, 37), ephinephrine or norepinephrine (38), and subclinical liver disease or hepatic insulin resistance (39).…”
Section: Discussionmentioning
confidence: 99%
“…With the dominant role of the liver in the regulation of total IGF-I levels it is conceivable that baseline levels of total, free and bioactive IGF-I are lower in liver cirrhosis as normal secretion of IGF-I in response to GH stimulation is attenuated [29]. This effect is not overridden by the higher than normal IGFBP-1 and IGFBP-2 levels described under this condition [29].…”
Section: Disease Specific Alterations In Igf-imentioning
confidence: 99%
“…With the dominant role of the liver in the regulation of total IGF-I levels it is conceivable that baseline levels of total, free and bioactive IGF-I are lower in liver cirrhosis as normal secretion of IGF-I in response to GH stimulation is attenuated [29]. This effect is not overridden by the higher than normal IGFBP-1 and IGFBP-2 levels described under this condition [29]. We recently demonstrated this close relationship of the degree of liver failure to IGF-I levels in patients with varying degrees of liver cirrhosis where IGF-I levels correlated inversely to the degree of liver damage (Brabant et al, unpublished results).…”
Section: Disease Specific Alterations In Igf-imentioning
confidence: 99%
“…Patients with cirrhosis and portal hypertension are known to have significant changes in their insulin-like growth factor (IGF) system and its interaction with insulin that may play a role for their loss of body mass (6)(7)(8)(9). Therefore, it is an obvious possibility that TIPS changes the prevailing IGF system and insulin levels in a way that contributes towards improved nutrition (10)(11)(12).…”
Section: Introductionmentioning
confidence: 99%